Design Therapeutics, Inc.

US$10.21As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:DSGNHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (17.44%)
Div yield —
ROE (36.87%)
Biotechnology
Beta (5Y) 1.75
PE TTM —
TSR TTM 52.39%
Mkt cap US$653.8M
ROIC (25.20%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$12
14.96%
(23.49%)
Hold 6|8|9|6|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.21
0.20
0.20
0.22
11.27%
9.53%
10.78%
9.19%
Revenue$M
68.38
71.94
75.99
78.68
8.57%
15.16%
18.28%
17.03%
Peers (US$653.8M)
Cap (US$)
PE
654.6M
—
Capital
TTM
5Y
10Y
Leveragex
0.503
0.142
0.142
EBIT/Intx
1.734
0.150
0.153
Own earn%
(104.87)
(11.81)
(11.83)
Sh yield%
16.32
24.83
24.47
Owners
Insiders/Inst%
10.42
89.51
Short interest%
1.96
SBC / revenue%
5.43
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
16–22
$1 testx
0.4
Incr. ROIC%
4